Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $1.68 in the prior trading day, Clover Health Investments Corp (NASDAQ: CLOV) closed at $1.66, down -1.19%. In other words, the price has decreased by -$1.19 from its previous closing price. On the day, 2.64 million shares were traded. CLOV stock price reached its highest trading level at $1.7097 during the session, while it also had its lowest trading level at $1.65.
Ratios:
Our goal is to gain a better understanding of CLOV by taking a closer look at its different ratios. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Cowen on February 02, 2022, Upgraded its rating to Market Perform and sets its target price to $3 from $7 previously.
On February 02, 2022, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $6.
On January 19, 2022, SVB Leerink started tracking the stock assigning a Mkt Perform rating and target price of $3.SVB Leerink initiated its Mkt Perform rating on January 19, 2022, with a $3 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 17 ’24 when Garipalli Vivek bought 877,567 shares for $1.14 per share. The transaction valued at 1,000,426 led to the insider holds 877,567 shares of the business.
Loengard Anna U bought 10,000 shares of CLOV for $9,300 on May 17 ’24. The Director now owns 10,000 shares after completing the transaction at $0.93 per share. On May 16 ’24, another insider, Loengard Anna U, who serves as the Director of the company, bought 17,085 shares for $0.96 each. As a result, the insider paid 16,372 and bolstered with 15,600 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLOV now has a Market Capitalization of 834015552 and an Enterprise Value of 486072192. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.45 while its Price-to-Book (P/B) ratio in mrq is 2.75. Its current Enterprise Value per Revenue stands at 0.236 whereas that against EBITDA is -3.711.
Stock Price History:
The Beta on a monthly basis for CLOV is 2.14, which has changed by 0.4561404 over the last 52 weeks, in comparison to a change of 0.21656322 over the same period for the S&P500. Over the past 52 weeks, CLOV has reached a high of $1.78, while it has fallen to a 52-week low of $0.61. The 50-Day Moving Average of the stock is 40.34%, while the 200-Day Moving Average is calculated to be 71.38%.
Shares Statistics:
The stock has traded on average 5.93M shares per day over the past 3-months and 4534580 shares per day over the last 10 days, according to various share statistics. A total of 393.27M shares are outstanding, with a floating share count of 375.13M. Insiders hold about 24.44% of the company’s shares, while institutions hold 18.02% stake in the company. Shares short for CLOV as of 1719532800 were 35160470 with a Short Ratio of 5.93, compared to 1717113600 on 38082918. Therefore, it implies a Short% of Shares Outstanding of 35160470 and a Short% of Float of 8.7799996.
